Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Capital Expenditures (2024 - 2025)

Bioregenx's Capital Expenditures history spans 2 years, with the latest figure at $3057.0 for Q4 2025.

  • Quarterly results put Capital Expenditures at $3057.0 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $9057.0 (down 95.22% YoY), and the annual figure for FY2025 was $9057.0, down 95.22%.
  • Capital Expenditures for Q4 2025 was $3057.0 at Bioregenx, down from $6000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $189390.0 in Q1 2024 to a low of $3057.0 in Q4 2025.